CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis

Heinz August Horst; Gerhard Zugmaier; Giovanni Martinelli; Noemi Mergen; Kelly Velasco; Faraz Zaman; Hagop Kantarjian

doi:10.1002/ajh.26988

CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis

Heinz August Horst, Gerhard Zugmaier, Giovanni Martinelli, Noemi Mergen, Kelly Velasco, Faraz Zaman, Hagop Kantarjian

Leukemia

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E222-E225
Journal	American journal of hematology
Volume	98
Issue number	8
DOIs	https://doi.org/10.1002/ajh.26988
State	Published - Aug 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26988

Cite this

CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. / Horst, Heinz August; Zugmaier, Gerhard; Martinelli, Giovanni et al.
In: American journal of hematology, Vol. 98, No. 8, 08.2023, p. E222-E225.

Research output: Contribution to journal › Letter › peer-review

@article{73555433e2534f62a0802838ea0adb4c,

title = "CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis",

author = "Horst, {Heinz August} and Gerhard Zugmaier and Giovanni Martinelli and Noemi Mergen and Kelly Velasco and Faraz Zaman and Hagop Kantarjian",

note = "Funding Information: The authors thank all the site investigators and patients who participated in the study. Swapnil Kher, PhD, of Cactus Life Sciences (part of Cactus Communications) provided medical writing assistance funded by Amgen Inc. Bob Dawson (Cactus Communications, on behalf of Amgen Inc.) provided graphics support. ",

year = "2023",

month = aug,

doi = "10.1002/ajh.26988",

language = "English (US)",

volume = "98",

pages = "E222--E225",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis

AU - Horst, Heinz August

AU - Zugmaier, Gerhard

AU - Martinelli, Giovanni

AU - Mergen, Noemi

AU - Velasco, Kelly

AU - Zaman, Faraz

AU - Kantarjian, Hagop

N1 - Funding Information: The authors thank all the site investigators and patients who participated in the study. Swapnil Kher, PhD, of Cactus Life Sciences (part of Cactus Communications) provided medical writing assistance funded by Amgen Inc. Bob Dawson (Cactus Communications, on behalf of Amgen Inc.) provided graphics support.

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85163192168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163192168&partnerID=8YFLogxK

U2 - 10.1002/ajh.26988

DO - 10.1002/ajh.26988

M3 - Letter

C2 - 37345570

AN - SCOPUS:85163192168

SN - 0361-8609

VL - 98

SP - E222-E225

JO - American journal of hematology

JF - American journal of hematology

IS - 8

ER -

CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this